Inflammatory effects of prostacyclin (PGI2) and 6-oxo-PGF1alpha in the rat paw.
In the rat paw prostacyclin was 5--10 times less potent than PGE2 in causing oedema, and 5 times less potent in potentiating carrageenin-induced oedema, which it did in a dose-related manner. Prostacyclin was 5 times more potent than PGE2 in producing hyperalgesia and as potent as PGE2 in restoring carrageenin-induced hyperalgesia. The effects on oedema were longer lasting than those on hyperalgesia. 6-oxo-PGF1alpha was 500 times less potent than PGE2 in causing oedema by itself and in potentiating carrageenin-induced oedema. It had no hyperalgesic activity in this test.
D000818:Animals; D002351:Carrageenan / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004487:Edema / Q000139:chemically induced*; D011464:Epoprostenol / Q000008:administration & dosage; D006614:Hindlimb; D006930:Hyperalgesia / Q000139:chemically induced; D007267:Injections; D008297:Male; D011453:Prostaglandins / Q000008:administration & dosage; D011458:Prostaglandins E / Q000008:administration & dosage; D011460:Prostaglandins F / Q000008:administration & dosage; D051381:Rats
D011453:Prostaglandins; D011458:Prostaglandins E; D011460:Prostaglandins F; D002351:Carrageenan; D011464:Epoprostenol